Pulmotect announced that it has raised $5.9 million in a Series C funding to support a Phase 2 trial of the company's PUL-042 immunostimulant inhalation solution. According to Pulmotect, the new funds will be used along with an $8.9 million Product Development Research grant awarded last year by the Cancer Prevention and Research Institute of Texas (CPRIT) for the … [Read more...] about Pulmotect raises $5.9 million in Series C funding to support Phase 2 trial of PUL-042 inhalation solution in cancer patients
Business
Vectura to be acquired by Phillips Medisize parent Molex
Inhalation CDMO Vectura has been sold to Molex for £150 million up front and up to an additional £148 million in potential payments, the companies have announced. Following the acquisition, Vectura will be operated by Phillips Medisize, which was acquired by Molex in 2016. The sale is expected to close by the end of this year. According to the Vectura Fertin press … [Read more...] about Vectura to be acquired by Phillips Medisize parent Molex
Nuance to market Altamira’s Bentrio bentonite-based nasal spray in additional Asian countries
Altamira Therapeutics has announced an extension of its 2022 license and distribution agreement that gave Nuance Pharma the rights to market Altamira's Bentrio nasal spray in China, Hong Kong, Macau and South Korea. According to Altamira, Nuance has recently submitted a marketing application for Bentrio in China. The revised deal adds Singapore, Malaysia, Thailand, … [Read more...] about Nuance to market Altamira’s Bentrio bentonite-based nasal spray in additional Asian countries
Roivant’s Pulmovant subsidiary developing mosliciguat DPI licensed from Bayer for the treatment of PH-ILD
Roivant has revealed that its Pulmovant subsidiary is developing inhaled dry powder mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), and Pulmovant presented a poster with data from the Phase 1b ATMOS study of mosliciguat at the 2024 ERS Congress. Roivant says that it paid approximately $14 million up front … [Read more...] about Roivant’s Pulmovant subsidiary developing mosliciguat DPI licensed from Bayer for the treatment of PH-ILD
ENA Respiratory gets additional funding from the US Department of Defense for development of INNA-051 intranasal antiviral
ENA Respiratory announced that it has received a contract extension from the US Department of Defense (DoD), providing additional funds for continued development of INNA-051, a dry powder intranasal TLR2/6 agonist. In January 2023, ENA Respiratory announced that the DoD had provided funding to develop a dry powder formulation of the antiviral, which had previously … [Read more...] about ENA Respiratory gets additional funding from the US Department of Defense for development of INNA-051 intranasal antiviral
Liquidia files suit to challenge FDA’s grant of exclusivity to Tyvaso DPI in ongoing litigation over Yutrepia DPI approval
Soon after the FDA granted temporary approval to Liquidia's sNDA for Yutrepia treprostinil DPI, the company announced that it has filed a lawsuit challenging the FDA's grant of 3-year new clinical investigation exclusivity to United Therapeutics' Tyvaso treprostinil DPI, which is standing in the way of final approval of Yutrepia. Exclusivity for Tyvaso DPI is … [Read more...] about Liquidia files suit to challenge FDA’s grant of exclusivity to Tyvaso DPI in ongoing litigation over Yutrepia DPI approval
Pharma Nordic acquires Swedish and Danish rights to Altamira’s Bentrio bentonite-based nasal spray
Pharma Nordic has expanded its distribution agreement with Altamira Medica for Bentrio nasal spray, adding Sweden and Denmark, the companies announced. Bentrio is an OTC bentonite-based nasal spray gel marketed for the prevention and treatment of allergic rhinitis. In July 2023, Pharma Nordic acquired the distribution rights for Bentrio in Norway, and the company … [Read more...] about Pharma Nordic acquires Swedish and Danish rights to Altamira’s Bentrio bentonite-based nasal spray
Proveca acquires global rights to Cessatech’s CT001 sufentanil / ketamine nasal spray
Cessatech and pediatric medicines specialist Proveca have announced a deal that gives Proveca global commercialization rights to Cessatech's CT001 sufentanil / ketamine analgesic nasal spray. Earlier this year, Cessatech initiated a Phase 3 trial of CT001 in children with moderate-to-severe pain under care in the emergency department. According to the … [Read more...] about Proveca acquires global rights to Cessatech’s CT001 sufentanil / ketamine nasal spray
De Motu Cordis announces expansion of deal with Catalent for services related to development of DMC-IH1 epinephrine DPI
Australian pharma company De Motu Cordis (DMC), which is developing an epinephrine DPI for the treatment of anaphylaxis, announced that it has contracted with Catalent for product assembly, expanding a November 2022 deal with the CDMO that covered formulation and manufacturing. The extension of the deal will provide manufacturing and assembly services through a … [Read more...] about De Motu Cordis announces expansion of deal with Catalent for services related to development of DMC-IH1 epinephrine DPI
Merz Therapeutics acquires Inbrija levodopa DPI from Acorda
Merz Therapeutics announced that it has acquired Inbrija inhaled dry powder levodopa from Acorda Therapeutics, which declared bankruptcy earlier this year. Merz had served as a "stalking horse bidder" for the Acorda assets, which also included Fampyra. Inbrija has been approved treatment of OFF episodes in Parkinson’s disease patients since December 2018 in the US … [Read more...] about Merz Therapeutics acquires Inbrija levodopa DPI from Acorda